PL360591A1 - Pochodne chinazoliny - Google Patents

Pochodne chinazoliny

Info

Publication number
PL360591A1
PL360591A1 PL01360591A PL36059101A PL360591A1 PL 360591 A1 PL360591 A1 PL 360591A1 PL 01360591 A PL01360591 A PL 01360591A PL 36059101 A PL36059101 A PL 36059101A PL 360591 A1 PL360591 A1 PL 360591A1
Authority
PL
Poland
Prior art keywords
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
PL01360591A
Other languages
English (en)
Other versions
PL202812B1 (pl
Inventor
Laurent Francoise Andre Hennequin
Patrick Ple
Christine Marie Paul Lambert
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL360591A1 publication Critical patent/PL360591A1/pl
Publication of PL202812B1 publication Critical patent/PL202812B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL360591A 2000-08-21 2001-08-15 Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie PL202812B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00402320 2000-08-21
EP01401006 2001-04-19
PCT/GB2001/003649 WO2002016352A1 (en) 2000-08-21 2001-08-15 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
PL360591A1 true PL360591A1 (pl) 2004-09-06
PL202812B1 PL202812B1 (pl) 2009-07-31

Family

ID=26073540

Family Applications (1)

Application Number Title Priority Date Filing Date
PL360591A PL202812B1 (pl) 2000-08-21 2001-08-15 Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie

Country Status (21)

Country Link
US (1) US7115615B2 (pl)
EP (1) EP1313727A1 (pl)
JP (1) JP2004506732A (pl)
KR (2) KR20080027400A (pl)
CN (1) CN100347169C (pl)
AR (1) AR033560A1 (pl)
AU (2) AU2001278609B2 (pl)
BR (1) BR0113358A (pl)
CA (1) CA2419301C (pl)
CZ (1) CZ2003486A3 (pl)
EE (1) EE05387B1 (pl)
IL (2) IL154131A0 (pl)
MX (1) MXPA03001332A (pl)
MY (1) MY129809A (pl)
NO (1) NO326515B1 (pl)
NZ (1) NZ523702A (pl)
PL (1) PL202812B1 (pl)
RU (1) RU2267489C2 (pl)
SK (1) SK2142003A3 (pl)
TW (1) TWI280960B (pl)
WO (1) WO2002016352A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
AU2001292137A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
ES2272737T3 (es) 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
GB0128109D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
AU2002365664A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
CN101607958A (zh) * 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ATE429230T1 (de) * 2002-07-09 2009-05-15 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
CN100354278C (zh) * 2002-11-04 2007-12-12 阿斯利康(瑞典)有限公司 作为src酪氨酸激酶抑制剂的喹唑啉衍生物
WO2004041829A1 (en) * 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
RS20060097A (en) 2002-12-20 2008-11-28 Pfizer Products Inc., Pyrimidine derivatives for the treatment of abnormal cell growth
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
EP2612853A1 (en) 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
BRPI0510980A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento do crescimento anormal de células
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
AU2005295788A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
CN101243030B (zh) * 2005-08-17 2012-02-01 宇部兴产株式会社 4-卤代邻苯二酚化合物的制备方法
AU2007274284B2 (en) * 2006-07-13 2012-04-26 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
ES2699585T3 (es) 2006-12-15 2019-02-11 Nantbio Inc Derivados de triazina y sus aplicaciones terapéuticas
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
US20100069340A1 (en) * 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
AU2009295948B2 (en) * 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
CA2765044A1 (en) 2009-06-09 2010-12-16 California Capital Equity, Llc Benzyl substituted triazine derivatives and their therapeutical applications
BRPI1011318A2 (pt) 2009-06-09 2019-09-24 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN102617463A (zh) * 2012-02-28 2012-08-01 苏州卡耐博生物技术有限公司 喹啉衍生物和喹唑啉衍生物及它们的制备方法
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
EP3781561B1 (en) 2018-04-18 2024-03-13 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN116120273A (zh) * 2023-02-15 2023-05-16 爱斯特（成都）生物制药股份有限公司 一种制备5-溴苯并[d][1,3]二氧-4-胺的方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5411963A (en) 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
CZ288955B6 (cs) 1994-02-23 2001-10-17 Pfizer Inc. Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pl) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
DK0912559T3 (da) 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AUPO257096A0 (en) * 1996-09-25 1996-10-17 Bhp Steel (Jla) Pty Limited Production of striped coatings on strip
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
MXPA01001893A (es) 1998-08-21 2002-04-24 Parker Hughes Inst Derivados de quinazolina.
CN1161352C (zh) 1998-10-08 2004-08-11 阿斯特拉曾尼卡有限公司 喹唑啉衍生物
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
KR100838617B1 (ko) * 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
AU3281600A (en) 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SK3832002A3 (en) 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EP1274692B1 (en) 2000-04-07 2006-08-02 AstraZeneca AB Quinazoline compounds
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001292137A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
AU2002212436A1 (en) 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
ES2272737T3 (es) 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.

Also Published As

Publication number Publication date
MY129809A (en) 2007-05-31
AU2001278609B2 (en) 2005-04-14
CN100347169C (zh) 2007-11-07
MXPA03001332A (es) 2004-07-08
EE05387B1 (et) 2011-02-15
IL154131A0 (en) 2003-07-31
RU2267489C2 (ru) 2006-01-10
EE200300071A (et) 2004-12-15
CZ2003486A3 (cs) 2003-05-14
NZ523702A (en) 2004-08-27
JP2004506732A (ja) 2004-03-04
BR0113358A (pt) 2003-07-01
KR20080027400A (ko) 2008-03-26
EP1313727A1 (en) 2003-05-28
US20040034046A1 (en) 2004-02-19
CA2419301A1 (en) 2002-02-28
US7115615B2 (en) 2006-10-03
TWI280960B (en) 2007-05-11
NO20030795L (no) 2003-04-04
WO2002016352A1 (en) 2002-02-28
NO326515B1 (no) 2008-12-22
KR20030022416A (ko) 2003-03-15
SK2142003A3 (en) 2003-07-01
KR100821446B1 (ko) 2008-04-10
IL154131A (en) 2010-04-15
PL202812B1 (pl) 2009-07-31
AR033560A1 (es) 2003-12-26
CN1471527A (zh) 2004-01-28
CA2419301C (en) 2009-12-08
AU7860901A (en) 2002-03-04
NO20030795D0 (no) 2003-02-20

Similar Documents

Publication Publication Date Title
AU7860901A (en) Quinazoline derivatives
HK1092804A1 (en) New quinazoline derivatives
HUP0301330A3 (en) 2-aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
IL153754A0 (en) Pyrimidine derivatives
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
AU2002212436A1 (en) Quinazoline derivatives
HK1078079A1 (en) Pyrimidine derivatives
AU2001292137A1 (en) Quinazoline derivatives
IL155103A0 (en) Substituted c-cyclohexylmethylamine derivatives
IL155106A0 (en) Substituted 1-aminobutan-3-ol derivatives
IL150557A0 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
PL356565A1 (pl) Pochodne aminosulfonylobifenylu
IL150558A0 (en) Aminomethyl-phenyl-cyclohexanone derivatives
AU2163202A (en) 5-amino-1-pentene-3-ol substituted derivatives
IL151598A0 (en) 2-phenylpyran-4-one derivatives
GB0030989D0 (en) Quinazoline derivatives
GB0015376D0 (en) Quinazoline derivatives
GB0021639D0 (en) Maurotoxin derivatives
HK1054937A1 (en) 1-Methylcarbapenem derivatives
SI1303496T1 (sl) Pirimidinski derivati

Legal Events

Date Code Title Description
RECP Rectifications of patent specification
LAPS Decisions on the lapse of the protection rights

Effective date: 20110815